Developer docs
API playgroundTry for free, no card

Search company profiles

Vanquish

Full company profile

uuid0027lu6

Namestring
Vanquish
Legal namestring
Grupo Vanquish de México, S.A. de C.V.
Company typeenum
Private
Founded yearint
1979
Descriptiontext

Grupo Vanquish is a privately held, 100% Mexican integrated pharmaceutical group headquartered in Mexico City, operating since 1979 across the full healthcare value chain through five wholly-owned subsidiaries plus the Emerge Lab brand. The group's core technology footprint is concentrated in solid oral and effervescent pharmaceutical formulations, manufacturing of advanced-technology medical devices, and the patented active ingredient Calcium Gluconolactate for osteoporosis treatment (patented 2002). Primary production assets are located in Civac, Morelos, where the original API and finished-dose manufacturing operations have been based for over four decades.

The company operates three interconnected business axes: (1) manufacturing of medicines and medical devices through Laboratorios Vanquish and Emerge Lab; (2) commercialization of licensed medicines and OTC supplements through Mirei Pharma, distribution to pharmacies and supermarkets, an in-house e-commerce pharmacy platform, and B2B licensing for domestic and international markets; and (3) integrated 4PL logistics operated by Vantage Servicios Integrales de Salud, distributing over 2,500 SKUs nationwide with cold and dry chain capabilities to public sector institutions, healthcare providers, and other pharmaceutical laboratories. The company entered international markets between 2019 and 2024 and has stated a strategic goal of ranking among the top five healthcare enterprises in Latin America by 2030.

Revenue is generated through a mix of one-time manufacturing contracts, licensing and royalty arrangements, managed logistics services, and direct e-commerce transactions. The customer base spans Mexican public sector procurement, private pharmacies, supermarket chains, healthcare institutions, and international B2B partners. Grupo Vanquish is founder-controlled and self-funded, with no disclosed external equity, debt, or public listing, and its ownership and corporate structure have not been reported as having undergone material change.

Short descriptiontext

Grupo Vanquish is a privately held, 100% Mexican integrated pharmaceutical group that develops, manufactures, commercializes, and distributes medicines, supplements, and medical devices in Mexico and selected international markets through five subsidiaries and over 2,500 SKUs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCiudad De Mérida, Mexico
HQ citystring
Ciudad De Mérida
HQ countrystring
Mexico
HQ regionstring
Latin America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, effervescent medicines, pharmaceutical distribution logistics, medical supplies wholesale, pharmaceutical licensing
Industry2 codes
PRIMARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Manufacturing
TypeOne Time License
Description

Development and manufacturing of solid and effervescent oral medicines, and advanced technology medical devices

grupovanquish.com.mx
2Commercialization
TypeLicensing Royalties
Description

Commercialization of licensed medicines and supplements for private and public markets through B2B models

grupovanquish.com.mx
3Distribution and Logistics
TypeManaged Services
Description

Integral logistics operations covering distribution of medicines and medical supplies nationwide with over 2,500 SKUs for public sector

grupovanquish.com.mx
4E-commerce
TypeTransaction Fee
Description

Dynamic e-commerce platform for pharmacy products serving end consumers

grupovanquish.com.mx
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Grupo Vanquish is a Mexican pharmaceutical group that develops, manufactures, and commercializes solid oral and effervescent medicines, OTC supplements, and advanced-technology medical devices through its subsidiaries Laboratorios Vanquish, Mirei Pharma, Vanquish Farmacéutica, and Emerge Lab. It also operates 4PL logistics services through Vantage Servicios Integrales de Salud, distributing medicines and medical supplies with over 2,500 SKUs across Mexico via cold and dry chain networks to public and private sector customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 2,500 SKUs supplied to public sector
+2 more records
Product overview1 text field

Grupo Vanquish operates as an integrated pharmaceutical group with five subsidiaries offering a full-spectrum healthcare value chain. The portfolio centers on three core business axes: (1) Manufacturing through Laboratorios Vanquish and Emerge Lab, producing solid oral and effervescent medicines plus medical devices; (2) Commercialization via Mirei Pharma and the company's own licensing operations, distributing medicines and supplements through pharmacies, supermarkets, and e-commerce platforms to both private and public sectors; and (3) Logistics through Vantage Servicios Integrales de Salud, providing 4PL services with over 2,500 SKUs across cold and dry chain networks nationwide. The group also holds a patent for Calcium Gluconolactate for osteoporosis treatment (2002) and entered international markets in 2019.

Product and service4 records
1Manufacturing of Medicines and Medical Devices
CategoryPharmaceutical Manufacturing Services
Description

Contract and proprietary development and manufacturing of solid oral medicines, effervescent formulations, and advanced-technology medical devices through Laboratorios Vanquish and Emerge Lab facilities in Morelos, Mexico. Customers include private pharmaceutical companies and the Mexican public healthcare sector.

2Commercialization of Medicines and Supplements
CategoryPharmaceutical Commercialization and Licensing
Description

Licensing and B2B distribution of proprietary medicines, OTC supplements, and the Mirei Pharma brand portfolio to pharmacies, supermarkets, and international partners, plus a direct e-commerce pharmacy channel serving end consumers in Mexico.

3Integral Logistics Operations (4PL)
CategoryPharmaceutical Logistics and Distribution
Description

Fourth Party Logistics services operated through Vantage Servicios Integrales de Salud, importing medical supplies from origin and delivering last-mile throughout Mexico with cold and dry chain capabilities. Manages over 2,500 SKUs of medicines and medical supplies for public sector healthcare institutions and pharmaceutical laboratories nationwide.

4Calcium Gluconolactate (Gluconolactato de Calcio) Active Ingredient
CategoryPatented Active Pharmaceutical Ingredient
Description

Patented active pharmaceutical ingredient (principio activo) developed and patented by Grupo Vanquish for the treatment of osteoporosis, available for licensing and use in pharmaceutical formulations.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Laboratorios Vanquish, S.A. de C.V.
Strategic tierCoreTypeOthers
Description

Subsidiary company of Grupo Vanquish, part of the pharmaceutical group structure including Grupo Vanquish de México, Mirei Pharma de México, Vantage Servicios Integrales de Salud, and Vanquish Farmacéutica

grupovanquish.com.mx
2Mirei Pharma de México, S.A. de C.V.
Strategic tierCoreTypeOthers
Description

Subsidiary company of Grupo Vanquish focused on pharmaceutical products and services

grupovanquish.com.mx
3Vantage Servicios Integrales de Salud, S.A. de C.V.
Strategic tierCoreTypeOthers
Description

Subsidiary company of Grupo Vanquish providing integrated healthcare services

grupovanquish.com.mx
4Vanquish Farmacéutica, S.A. de C.V.
Strategic tierCoreTypeOthers
Description

Subsidiary company of Grupo Vanquish focused on pharmaceutical operations

grupovanquish.com.mx
5Grupo Vanquish de México, S.A. de C.V.
Strategic tierCoreTypeOthers
Description

Parent/holding company of Grupo Vanquish group, the main entity overseeing subsidiaries

grupovanquish.com.mx
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Bayer de México
TypeBroad incumbent
Description

Multinational pharmaceutical and consumer health incumbent operating broadly in Mexico; relevant benchmark for scale, regulatory capability, and consumer brand reach that Grupo Vanquish's OTC and portfolio strategies must compete against.

2Laboratorios PiSA (Grupo PiSA)
TypeDirect peer
Description

One of Mexico's largest integrated pharmaceutical groups with manufacturing, distribution, and public/private market commercialization across 2,000+ SKUs; most directly comparable peer given similar nationwide Mexican footprint and public-sector supply orientation.

3Eurofarma
TypeRegional player
Description

Brazilian pharmaceutical multinational with a growing LatAm footprint across manufacturing and distribution; most relevant regional peer for benchmarking Grupo Vanquish's stated Top-5 LATAM healthcare ambition by 2030.

TypeDirect peer
Description

Mexican pharmaceutical manufacturer with significant private and public sector presence; comparable on domestic manufacturing scale and on serving Mexican government drug procurement programs.

5Laboratorios Chinoin
TypeEmerging player
Description

Mexican pharmaceutical manufacturer with branded generics and OTC presence; comparable niche player operating alongside Vanquish in Mexican private and OTC channels with similar therapeutic-area focus.

6Probiomed
TypeDirect peer
Description

Mexican biopharmaceutical manufacturer with biologics, generics, and public-sector supply capability; comparable on the combination of domestic API/finished-dose manufacturing and integration into Mexican institutional channels.

TypeDirect peer
Description

Mexico-based OTC and consumer healthcare company with strong retail, supermarket, and pharmacy distribution; directly comparable on Mexican OTC channel strategy and brand-led commercialization.

8Sanofi México
TypeBroad incumbent
Description

Multinational pharma with established Mexican manufacturing and strong public-sector franchise (vaccines, primary care); relevant benchmark for what a broad multinational incumbent offers versus a focused local player in the same public tenders.

9Grupo EMS
TypeRegional player
Description

Brazilian pharmaceutical group with multi-country LatAm presence and broad generic/OTC portfolio; useful regional comparable for assessing how Grupo Vanquish's portfolio and channel strategy could translate outside Mexico.

TypeBroad incumbent
Description

Multinational pharmaceutical incumbent across prescription, vaccines, and public-sector supply in Mexico; comparable on tender participation and on serving government healthcare institutions at large scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vanquish

Pharmaceutical Manufacturinggrupovanquish.com.mx

Grupo Vanquish is a privately held, 100% Mexican integrated pharmaceutical group that develops, manufactures, commercializes, and distributes medicines, supplements, and medical devices in Mexico and selected international markets through five subsidiaries and over 2,500 SKUs.

What Vanquish does

Grupo Vanquish is a privately held, 100% Mexican integrated pharmaceutical group headquartered in Mexico City, operating since 1979 across the full healthcare value chain through five wholly-owned subsidiaries plus the Emerge Lab brand. The group's core technology footprint is concentrated in solid oral and effervescent pharmaceutical formulations, manufacturing of advanced-technology medical devices, and the patented active ingredient Calcium Gluconolactate for osteoporosis treatment (patented 2002). Primary production assets are located in Civac, Morelos, where the original API and finished-dose manufacturing operations have been based for over four decades.

The company operates three interconnected business axes: (1) manufacturing of medicines and medical devices through Laboratorios Vanquish and Emerge Lab; (2) commercialization of licensed medicines and OTC supplements through Mirei Pharma, distribution to pharmacies and supermarkets, an in-house e-commerce pharmacy platform, and B2B licensing for domestic and international markets; and (3) integrated 4PL logistics operated by Vantage Servicios Integrales de Salud, distributing over 2,500 SKUs nationwide with cold and dry chain capabilities to public sector institutions, healthcare providers, and other pharmaceutical laboratories. The company entered international markets between 2019 and 2024 and has stated a strategic goal of ranking among the top five healthcare enterprises in Latin America by 2030.

Revenue is generated through a mix of one-time manufacturing contracts, licensing and royalty arrangements, managed logistics services, and direct e-commerce transactions. The customer base spans Mexican public sector procurement, private pharmacies, supermarket chains, healthcare institutions, and international B2B partners. Grupo Vanquish is founder-controlled and self-funded, with no disclosed external equity, debt, or public listing, and its ownership and corporate structure have not been reported as having undergone material change.

Vanquish firmographics

Firmographics
Name
Vanquish
Legal name
Grupo Vanquish de México, S.A. de C.V.
Website
https://grupovanquish.com.mx
Company type
Private
Founded year
1979
Operating status
Operating
Headcount range
101–250 employees
Short description
Grupo Vanquish is a privately held, 100% Mexican integrated pharmaceutical group that develops, manufactures, commercializes, and distributes medicines, supplements, and medical devices in Mexico and selected international markets through five subsidiaries and over 2,500 SKUs.
Ownership category
akta.pro rank

Vanquish industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • Pharmaceutical manufacturing
  • Effervescent medicines
  • Pharmaceutical distribution logistics
  • Medical supplies wholesale
  • Pharmaceutical licensing

Where Vanquish is headquartered

Location

Headquarters

HQ city
Ciudad De Mérida
HQ country
Mexico
HQ region
Latin America

Offices5 records

Markets served

Vanquish business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Manufacturing: Development and manufacturing of solid and effervescent oral medicines, and advanced technology medical devices
  2. Commercialization: Commercialization of licensed medicines and supplements for private and public markets through B2B models
  3. Distribution and Logistics: Integral logistics operations covering distribution of medicines and medical supplies nationwide with over 2,500 SKUs for public sector
  4. E-commerce: Dynamic e-commerce platform for pharmacy products serving end consumers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels4 records

Vanquish product offering

Product offering

Core offering

Grupo Vanquish is a Mexican pharmaceutical group that develops, manufactures, and commercializes solid oral and effervescent medicines, OTC supplements, and advanced-technology medical devices through its subsidiaries Laboratorios Vanquish, Mirei Pharma, Vanquish Farmacéutica, and Emerge Lab. It also operates 4PL logistics services through Vantage Servicios Integrales de Salud, distributing medicines and medical supplies with over 2,500 SKUs across Mexico via cold and dry chain networks to public and private sector customers.

Product overview

Grupo Vanquish operates as an integrated pharmaceutical group with five subsidiaries offering a full-spectrum healthcare value chain. The portfolio centers on three core business axes: (1) Manufacturing through Laboratorios Vanquish and Emerge Lab, producing solid oral and effervescent medicines plus medical devices; (2) Commercialization via Mirei Pharma and the company's own licensing operations, distributing medicines and supplements through pharmacies, supermarkets, and e-commerce platforms to both private and public sectors; and (3) Logistics through Vantage Servicios Integrales de Salud, providing 4PL services with over 2,500 SKUs across cold and dry chain networks nationwide. The group also holds a patent for Calcium Gluconolactate for osteoporosis treatment (2002) and entered international markets in 2019.

Differentiator

Problem solved

Functional benefit

Products and services

  • Manufacturing of Medicines and Medical Devices Contract and proprietary development and manufacturing of solid oral medicines, effervescent formulations, and advanced-technology medical devices through Laboratorios Vanquish and Emerge Lab facilities in Morelos, Mexico. Customers include private pharmaceutical companies and the Mexican public healthcare sector.
  • Commercialization of Medicines and Supplements Licensing and B2B distribution of proprietary medicines, OTC supplements, and the Mirei Pharma brand portfolio to pharmacies, supermarkets, and international partners, plus a direct e-commerce pharmacy channel serving end consumers in Mexico.
  • Integral Logistics Operations (4PL) Fourth Party Logistics services operated through Vantage Servicios Integrales de Salud, importing medical supplies from origin and delivering last-mile throughout Mexico with cold and dry chain capabilities. Manages over 2,500 SKUs of medicines and medical supplies for public sector healthcare institutions and pharmaceutical laboratories nationwide.
  • Calcium Gluconolactate (Gluconolactato de Calcio) Active Ingredient Patented active pharmaceutical ingredient (principio activo) developed and patented by Grupo Vanquish for the treatment of osteoporosis, available for licensing and use in pharmaceutical formulations.

Quantifiable outcome

  • Over 2,500 SKUs supplied to public sector
  • +2 more outcomes

Companies that use Vanquish

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Vanquish technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Vanquish partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Laboratorios Vanquish, S.A. de C.V.coreOthersSubsidiary company of Grupo Vanquish, part of the pharmaceutical group structure including Grupo Vanquish de México, Mirei Pharma de México, Vantage Servicios Integrales de Salud, and Vanquish Farmacéutica
  • Mirei Pharma de México, S.A. de C.V.coreOthersSubsidiary company of Grupo Vanquish focused on pharmaceutical products and services
  • Vantage Servicios Integrales de Salud, S.A. de C.V.coreOthersSubsidiary company of Grupo Vanquish providing integrated healthcare services
  • Vanquish Farmacéutica, S.A. de C.V.coreOthersSubsidiary company of Grupo Vanquish focused on pharmaceutical operations
  • Grupo Vanquish de México, S.A. de C.V.coreOthersParent/holding company of Grupo Vanquish group, the main entity overseeing subsidiaries

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Vanquish competitors and assessment

Company assessment

Broad incumbents

  • Bayer de México: Multinational pharmaceutical and consumer health incumbent operating broadly in Mexico; relevant benchmark for scale, regulatory capability, and consumer brand reach that Grupo Vanquish's OTC and portfolio strategies must compete against.
  • Sanofi México: Multinational pharma with established Mexican manufacturing and strong public-sector franchise (vaccines, primary care); relevant benchmark for what a broad multinational incumbent offers versus a focused local player in the same public tenders.
  • Pfizer México: Multinational pharmaceutical incumbent across prescription, vaccines, and public-sector supply in Mexico; comparable on tender participation and on serving government healthcare institutions at large scale.

Direct peers

  • Laboratorios PiSA (Grupo PiSA): One of Mexico's largest integrated pharmaceutical groups with manufacturing, distribution, and public/private market commercialization across 2,000+ SKUs; most directly comparable peer given similar nationwide Mexican footprint and public-sector supply orientation.
  • Laboratorios Silanes: Mexican pharmaceutical manufacturer with significant private and public sector presence; comparable on domestic manufacturing scale and on serving Mexican government drug procurement programs.
  • Probiomed: Mexican biopharmaceutical manufacturer with biologics, generics, and public-sector supply capability; comparable on the combination of domestic API/finished-dose manufacturing and integration into Mexican institutional channels.
  • Genomma Lab Internacional: Mexico-based OTC and consumer healthcare company with strong retail, supermarket, and pharmacy distribution; directly comparable on Mexican OTC channel strategy and brand-led commercialization.

Regional players

  • Eurofarma: Brazilian pharmaceutical multinational with a growing LatAm footprint across manufacturing and distribution; most relevant regional peer for benchmarking Grupo Vanquish's stated Top-5 LATAM healthcare ambition by 2030.
  • Grupo EMS: Brazilian pharmaceutical group with multi-country LatAm presence and broad generic/OTC portfolio; useful regional comparable for assessing how Grupo Vanquish's portfolio and channel strategy could translate outside Mexico.

Emerging players

  • Laboratorios Chinoin: Mexican pharmaceutical manufacturer with branded generics and OTC presence; comparable niche player operating alongside Vanquish in Mexican private and OTC channels with similar therapeutic-area focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Vanquish social profiles

Digital presence

Vanquish financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vanquish leadership team

Management profile

Number of profiles

Vanquish subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Vanquish funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vanquish M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vanquish

What does Vanquish do?

Grupo Vanquish is a Mexican pharmaceutical group that develops, manufactures, and commercializes solid oral and effervescent medicines, OTC supplements, and advanced-technology medical devices through its subsidiaries Laboratorios Vanquish, Mirei Pharma, Vanquish Farmacéutica, and Emerge Lab. It also operates 4PL logistics services through Vantage Servicios Integrales de Salud, distributing medicines and medical supplies with over 2,500 SKUs across Mexico via cold and dry chain networks to public and private sector customers.

Is Vanquish a public or private company?

Vanquish is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Vanquish founded?

Vanquish was founded in 1979. It employs 101 to 250 people.

Where is Vanquish based?

Vanquish is headquartered in Ciudad De Mérida, Mexico, in the Latin America region.

How does Vanquish make money?

Four revenue lines are on record. Manufacturing is the primary driver. The others are commercialization, distribution and Logistics and E-commerce.

Who are Vanquish's main competitors?

Broad incumbents on record are Bayer de México, Sanofi México and Pfizer México. Direct peers are Laboratorios PiSA (Grupo PiSA), Laboratorios Silanes, Probiomed and Genomma Lab Internacional. Regional players are Eurofarma and Grupo EMS. Laboratorios Chinoin is listed as an emerging player.

Does Vanquish have an API?

No public API is recorded for Vanquish.

What industry is Vanquish in?

Vanquish's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAJAF, Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor), with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales